Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

References for PMC Articles for PubMed (Select 18927277)

1.

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.

2.

A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.

Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein ML.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):7082-7. doi: 10.1073/pnas.0711263105. Epub 2008 May 6.

3.

Practical guidance for the management of aromatase inhibitor-associated bone loss.

Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M.

Ann Oncol. 2008 Aug;19(8):1407-16. doi: 10.1093/annonc/mdn164. Epub 2008 Apr 29.

4.

Communications between bone cells and hematopoietic stem cells.

Porter RL, Calvi LM.

Arch Biochem Biophys. 2008 May 15;473(2):193-200. doi: 10.1016/j.abb.2008.04.001. Epub 2008 Apr 7. Review.

5.

FRAX and the assessment of fracture probability in men and women from the UK.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E.

Osteoporos Int. 2008 Apr;19(4):385-97. doi: 10.1007/s00198-007-0543-5. Epub 2008 Feb 22.

6.

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.

Cancer. 2008 Mar 1;112(5):1001-10. doi: 10.1002/cncr.23259.

7.

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR.

Blood. 2008 Mar 1;111(5):2833-42. Epub 2007 Dec 19.

8.

New roles for osteoclasts in bone.

Boyce BF, Yao Z, Zhang Q, Guo R, Lu Y, Schwarz EM, Xing L.

Ann N Y Acad Sci. 2007 Nov;1116:245-54. Review.

PMID:
18083932
9.

Emerging strategies in bone health management for the adjuvant patient.

Coleman RE.

Semin Oncol. 2007 Dec;34(6 Suppl 4):S11-6. Review.

PMID:
18068485
10.

Increased lymphangiogenesis in joints of mice with inflammatory arthritis.

Zhang Q, Lu Y, Proulx ST, Guo R, Yao Z, Schwarz EM, Boyce BF, Xing L.

Arthritis Res Ther. 2007;9(6):R118.

11.

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

Lipton A, Cook RJ, Major P, Smith MR, Coleman RE.

Oncologist. 2007 Sep;12(9):1035-43.

12.

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S.

J Clin Oncol. 2007 Oct 1;25(28):4431-7. Epub 2007 Sep 4.

13.

Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R.

Cancer. 2007 Oct 15;110(8):1860-7.

14.

Detection and characterization of circulating and disseminated prostate cancer cells.

Morgan TM, Lange PH, Vessella RL.

Front Biosci. 2007 May 1;12:3000-9. Review.

PMID:
17485277
15.

Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V.

Clin Breast Cancer. 2007 Feb;7(6):471-9.

PMID:
17386124
16.

Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation.

Jung Y, Wang J, Song J, Shiozawa Y, Wang J, Havens A, Wang Z, Sun YX, Emerson SG, Krebsbach PH, Taichman RS.

Blood. 2007 Jul 1;110(1):82-90. Epub 2007 Mar 14.

17.

The role of the chemokine CXCL12 in osteoclastogenesis.

Gronthos S, Zannettino AC.

Trends Endocrinol Metab. 2007 Apr;18(3):108-13. Epub 2007 Feb 21. Review.

PMID:
17320408
18.

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P.

J Natl Cancer Inst. 2007 Feb 21;99(4):322-30.

19.

Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, van der Pluijm G, Löwik CW, Ackermann K, Pyerin W, Hamdy FC, Thalmann GN, Cecchini MG.

Am J Pathol. 2007 Jan;170(1):160-75.

20.

v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation.

Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y.

Nat Med. 2006 Dec;12(12):1403-9. Epub 2006 Nov 26.

PMID:
17128270
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk